show episodes
 
Being a trader takes confidence. In the markets, in your strategy, in your self – in having the confidence to execute that trade. In this unique series, we talk to the experts in their own fields to uncover what gives them the confidence to succeed. We also look at the dangers of overconfidence, and ways in which top performers keep their egos in check. Join us as we uncover confidence and unlock the secrets behind resilience, preparation, determination and growth - and how it can make you a ...
 
FDA CMC regulations and guidance simplified through examination, real life experiences and risk-based advice. This podcast hopes to educate sponsors and individuals on agency related regulatory CMC matters. We will focus on the critical CMC issues and build programs that enhance drug development. CMC topics will include Regulatory Starting Materials, API and Drug Product Process, Formulation Development, Supply Chains, Analytical Controls. Advocating and interpreting CMC Strategy, directing ...
 
Looking forward to hearing the latest buzz on how to scale your business? Dancho Dimkov, MSc, ExMBA, CMgr, CMC, CEO and Founder of BizzBee Solutions, President of MCA-2000, reflects on some of his daily life's most mundane and peculiar occurrences, providing you with something sweet to chew on. Who says that you can't take a shortcut to growth? Let Dancho's life stories pave your way to a successful B2B digital business and save you a mistake or two.
 
The Business of Biotech is the pod dedicated to leaders of emerging biopharma firms. We bring you insight into organizational, finance and funding, HR, clinical, manufacturing, and regulatory challenges you’ll face as you navigate your company from an idea to success in the clinic. Each episode features guest commentary and best practices from accomplished founders and biopharma industry luminaries. The Business of Biotech is produced by BioProcess Online and brought to you by Cytiva, former ...
 
What every business needs to survive and to grow are new clients. In the B2B world, new clients equal generating highly qualified sweet leads. Well, for BizzBee Solutions, the way to that was via outreach. Dancho Dimkov, MBA, CMC, CEO of BizzBee Solutions, author of "Sweet Leads" and BizzBee's Outreach COO - Natasha Razmoska reveal all their outreach knowledge and experience to this podcast's host Vera Eftimovska, MA, and BizzBee's Content COO. It's a dream team with tons of valuable insight ...
 
Merideth Bisiker, Certified Money Coach (CMC)® and mentor to entrepreneurs brings you industry experts who inspire you to find success in your business and in life on your own terms. These are powerful conversations that provide you with inspiring stories and strategies to rise above the mediocre and struggle you're facing now so you can finally live a life you love. Merideth and her guests inspire you to feel good about wanting to make money in your business so that you can make a bigger im ...
 
Loading …
show series
 
In episode #44 of Sweet Buzz - Scaling a Digital B2B Business With Dancho Dimkov, I talk about omnipresence. You already know that I'm present on social media. Specifically LinkedIn and Facebook. And I have sources of unique content, which is then redistributed to different platforms. My five sources of unique content are: 1. My book, "Sweet Leads"…
 
In episode #43 of Sweet Buzz - Scaling a Digital B2B Business With Dancho Dimkov, I talk about the ICP framework. Why is defining your Ideal Client Profile (ICP) of the utmost importance? First things first, you need to know who you're talking to. Second of all, you need to know whose problems you're good at solving. Just like people, no company or…
 
In business for just a decade, Akesobio's stats are mindboggling: 20 drug development programs, including 12 antibodies in clinical-stage development, six bi-specific antibodies (two at clinical stage), four antibodies with IND approvals from the FDA, and 22 clinical trials initiated. The company's CEO, Michelle Xia, Ph.D., sat down with the Busine…
 
In episode #42 of Sweet Buzz - Scaling a Digital B2B Business With Dancho Dimkov, I talk about what's the actual job of a trainer. I had an interesting thought I wanted to share with you. But, I want your feedback, too. And that's an obstacle I yet have to solve. So, back to the main topic, I'm working, day and night, on the BizzBee Online Academy.…
 
In episode #41 of Sweet Buzz - Scaling a Digital B2B Business With Dancho Dimkov, I talk about the importance of being a thought leader. As a person that comes from the freelancing world, I was never able to understand the significance of being a thought leader. Today, I have a completely different perspective. In honour of Global Entrepreneurship …
 
Homology Medicines' approaches to gene therapy and gene editing have the potential to seriously disrupt both the cell/gene therapy space and the mAb manufacturing and administration paradigms as we know them. On this episode of the Business of Biotech, Homology President & CEO Arthur Tzianabos, Ph.D. shares the company's approach and supports its r…
 
In episode #40 of Sweet Buzz - Scaling a Digital B2B Business With Dancho Dimkov, I talk about the ZZ framework. The ZZ framework is the synergy between marketing and sales. We've been using it in BizzBee Solutions, for quite some time now. To go back a little. BizzBee started six and a half years ago. At that moment, I was working as a management …
 
In episode #39 of Sweet Buzz - Scaling a Digital B2B Business With Dancho Dimkov, I talk about how I put my apartment for sale. Things are pretty exciting here. I don't know where to start. I caught myself applying the same business principles to everyday life. We are in the process of buying a new apartment, a bigger one. But, we have to sell the …
 
Dr. James Taylor believes that genomic medicine will prove the most revolutionary thing the life sciences industries have ever seen, and that it will ultimately become the largest therapeutic class. Dr. Taylor is president an CEO at Precision Nanosystems. He chalks up the genomic nature of biology, the fact that genomes are information-based, the b…
 
In episode #38 of Sweet Buzz - Scaling a Digital B2B Business With Dancho Dimkov, I talk about 100% Marketing Driven Sales vs 100% Sales Driven Sales. I don't talk enough about the B2B Sales topic. And yet, I have so much love and passion for it. As you already know, I published my first book "Sweet Leads" not long ago. It's one of the first concep…
 
In episode #37 of Sweet Buzz - Scaling a Digital B2B Business With Dancho Dimkov, I talk about the latest events in BizzBee Solutions and my private life. It's almost a week since my last episode of Sweet Buzz. Things here are hectic, and a lot of stuff is happening at the same time. It's already November, and that means less than two months until …
 
Is "flexible manufacturing" just another empty buzz concept concocted by the biopharma equipment marketing community, or does it demonstrate real benefit to bioprocess pros and their companies? On this episode, we sit down with Sarepta Therapeutics Director of Pharmaceutical Engineering Brian Winstead and Project Farma VP Tony Khoury to discuss wha…
 
While nary a day goes by without a shovel breaking ground on a new CDMO buildout, biopharmas remain hard-pressed to secure the outsourced manufacturing space and expertise needed to meet timelines, satisfy investors, and drive competitive advantage. On this episode of the Business of Biotech, we're tackling the CDMO capacity crunch from every angle…
 
In episode #36 of Sweet Buzz - Scaling a Digital B2B Business With Dancho Dimkov, I talk about an old dilemma. Can the business function without its head? Crazy things were happening, and it got me thinking. The question I wanted to address for today is, are you the business? Are you a one-man show? Could your company/business function properly wit…
 
The clinical trials status quo is a roadblock. They're slow, they're inefficient, and they're expensive. On this episode of the Business of Biotech, friend and frequent guest Allan Shaw shares some strong opinions on what's wrong with clinical trials, and what the industry (read: you) and the FDA need to do to make them right.…
 
In episode #35 of Sweet Buzz - Scaling a Digital B2B Business With Dancho Dimkov, I talk about the time you have for completing a task and Parkinson's Law. Hello, hello! Dancho here, the one with work filled up to his neck. This crazy busy period got me wondering. How are people managing to be efficient in using their precious time? In my college d…
 
In episode #34 of Sweet Buzz - Scaling a Digital B2B Business With Dancho Dimkov, I talk about re-evaluating myself on a business level. The one where it gets complicated and foggy. I think I have a mindset issue. Let's move on to the controversial "pricing" topic. How do you determine how much you should charge? How do you value your service? Peop…
 
Fresh on the heels of an outstanding talk with AltruBio President & CEO Judy Chou, Ph.D., the company's VP of Technology Development, Gene Lee, Ph.D., joins the Business of Biotech for a deep dive into the importance of CMC developability assessments. On this episode we cover the key points CMC developability assessments must address, when to begin…
 
In episode #33 of Sweet Buzz - Scaling a Digital B2B Business With Dancho Dimkov, I talk about some recent lifestyle changes. Yaay Friday! And I have so much to share with all of you. On a business level, but on a personal, too. So, I'm going to split it into two podcast episodes. Let me get started on the personal one. For the last four weeks, I'm…
 
In episode #32 of Sweet Buzz - Scaling a Digital B2B Business With Dancho Dimkov, I talk about the reflections of the book launch and the next steps. It was a long and stressful week. Well, I can say that the hard days are over. At the end of the first day of the book launch, September 29, "Sweet Leads" ended up on the "Amazon Best Sellers" - secon…
 
Inspired to develop a treatment for Infantile Krabbe Disease, the founders of Forge Biologics picked a unique but strategic approach to funding the initiative. They built a CDMO that aims to become one of the largest on the planet in the cell and gene therapy space. On this week's episode of the Business of Biotech podcast, co-founder, President, &…
 
In episode #31 of Sweet Buzz - Scaling a Digital B2B Business With Dancho Dimkov, I talk about the impressions of the official book launch days. How are things with you? Me? Oh, just another ordinary post-first-day book launch. You'll call me a liar if I say that I'm not genuinely happy and a little more than excited. 29th was a long day. So, I dec…
 
In episode #30 of Sweet Buzz - Scaling a Digital B2B Business With Dancho Dimkov, I talk about the official book launch and the sensational feeling that comes with it. Oh, the tension in the air, and the butterflies in my gut. Or, like some like to say, the calm before the storm. 29th and 30th September are nearly here. "Sweet Leads" is officially …
 
Eric Ostertag, M.D., Ph.D., wanted to launch a biotech. When University of Pennsylvania department heads said no to a licensing deal for lack of a CEO, Dr. Ostertag convinced them he could run the company. Many bold moves later, Dr. Ostertag is founder and CEO at Poseida Therapeutics, a company that's doing things never seen before in the field of …
 
In episode #29 of Sweet Buzz - Scaling a Digital B2B Business With Dancho Dimkov, I talk about the long-awaited book launch announcement. It's finally happening. I already did some podcast episodes about the book. We are currently preparing for a whole new podcast, especially devoted to the book. And, we set the dates. 29th and 30th of September, "…
 
In episode #28 of Sweet Buzz - Scaling a Digital B2B Business With Dancho Dimkov, I talk about reaching a goal of mine. This podcast officially has more than 1000 listeners. Since we launched "Sweet Buzz - Scaling a Digital B2B Business With Dancho Dimkov" in July, I have waited for this day. I wanted to record an episode mainly dedicated to reachi…
 
Judy Chou, Ph.D. was a big-pharma MVP. She earned her academic stripes in the hallowed halls of Yale, the Max Planck Institute, and Harvard Medical School before taking on principal scientist roles at AbbVie, Pfizer, and Genentech. That experience parlayed into SVP positions at Tanvex, Medvation, back to Pfizer, and on to Bayer, where she was most …
 
In episode #27 of Sweet Buzz - Scaling a Digital B2B Business With Dancho Dimkov, I talk about investing in clients' projects. I have a couple of questions for you. One of them is, are you investing in your client's projects? I want to share a story with a prospect who happens to be a business coach. And that's not an ordinary prospect we're talkin…
 
In episode #26 of Sweet Buzz - Scaling a Digital B2B Business With Dancho Dimkov, I talk about the cost of taking a piece of bad advice. We're all "thirsty" for getting a bit of advice, no doubt. And how many times we wanted to get it fast and inexpensive? We couldn't count it on both hands or both feet. But, what happens if you get a bad advice? T…
 
The biologic therapy market is crowded, and judging by the recent parade of IPOs, competition for investment, mindshare, talent, and ultimately share of market is only getting stiffer. On this week's episode of the Business of Biotech, our friend and biotech business guru Allan Shaw joins us for a foundational conversation on creating competitive d…
 
In episode #25 of Sweet Buzz - Scaling a Digital B2B Business With Dancho Dimkov, I talk about the fine line between old school and new school consulting. As a current President of MCA2000 - Management Consulting Association, I have the incredible opportunity to talk with many experienced consultants. They appreciate frameworks, formalities, concep…
 
In the 4th episode of the BizzBee podcast, "Sweet Leads, Dancho, Natasha and Vera discuss about: 1. From which services you can expect countless sweet leads? 2. Which services shouldn't even bother with outreach? 3. What you can do if you feel under the impression that outreach couldn't possibly work for you Check out Dancho's latest book on B2B pr…
 
In the 3rd episode of the BizzBee podcast, "Sweet Leads, Dancho, Natasha and Vera set the bar straight on what are warm leads. Or, as we like to call them - sweet leads. If someone schedules a meeting, can we hall them a sweet lead? Not every outreach campaign goal is to schedule a meeting. Are sweet leads relevant in this context? What do sweet le…
 
In the 2nd episode of the BizzBee podcast, "Sweet Leads, Dancho, Natasha and Vera talk on numerous topics: 1. Why should one decide on prospecting or outbound growth? 2. The difference between inbound and outbound 3. Why paid ads don't work? 4. Who does it work best for? 5. Is their ego/credibility affected when they do outreach? 6. Isn't it spammi…
 
The first episode of the BizzBee podcast "Sweet Leads" is out for the world to see. Or, to listen to is, in this case. The stars of the show? We swear by the B2B Outreach Bible, "Sweet Leads", you'll be in great company. 1. Dancho Dimkov, MBA, CMC, CEO of BizzBee Solutions, author of "Sweet Leads" 2. Natasha Razmoska, BizzBee's Outreach COO 3. Vera…
 
In episode #24 of Sweet Buzz - Scaling a Digital B2B Business With Dancho Dimkov, I talk about the focus on income-generating activities. I was reflecting on a mistake I was continuously doing for five years. For five years, I was concentrating on cutting and controlling costs. I bought computers and office essentials in order to make my employees …
 
Aruvant Chief Technology Officer Palani Palaniappan, Ph.D. joins the Business of Biotech with special guest Tony Khoury, EVP at Project Farma to discuss recent advances in gene therapy manufacturing. We cover the role of artificial intelligence in the discovery of AAV capsids that can avoid the immune system, the growth of non-viral vectors, the sc…
 
In episode #23 of Sweet Buzz - Scaling a Digital B2B Business With Dancho Dimkov, I talk about the curse of running an agency. There're advantages of running an agency, as well as disadvantages. In short, it is a rollercoaster. As you're growing your business, you have to raise salaries, you have to hire new people, you invest in various things. An…
 
In episode #22 of Sweet Buzz - Scaling a Digital B2B Business With Dancho Dimkov, I talk about the seven generations of beekeepers in the family. I decided to take a walk around the past. I was looking through some old photos, and I discovered two, that are like a pure treasure for me. The black and white one was from my great-great-grandfather, Me…
 
Dr. Ian Walters' company, Portage Biotech, is focused on addressing the 75% of cancer patients who show no, or limited, response to existing therapies such as checkpoint inhibitors. Leading that charge are the company's invariant natural killer T cell agonists, designed to activate the innate and adaptive immune system, as well as a growing portfol…
 
In episode #21 of Sweet Buzz - Scaling a Digital B2B Business With Dancho Dimkov, I talk about digital outreach fever definition. I feel a strong need to set a straight line for everything in B2B Business and B2B Sales. In my book, "Sweet Leads", I talk about digital outreach. But, I'm also focusing on the term "Digital Outreach Fever". We have cre…
 
In episode #20 of Sweet Buzz - Scaling a Digital B2B Business With Dancho Dimkov, I talk about the newest addition to our services. The number of this podcast's listeners are increasing by the minute. That's the one thing I'm happy about. Number two, things are not the same like they were a week ago. And in this episode, I have something new to ann…
 
Everyone in the business is looking for breakthroughs, but only a select few win breakthrough therapy designation from the FDA. Under the guidance of Ira Gupta, M.D. and Shanthi Ganeshan, Ph.D, GSK has a few BTDs under its belt. Dr. Gupta is VP of Medicine Development at GSK and Dr. Ganeshan is formerly VP of Global Regulatory Affairs there, having…
 
In episode #19 of Sweet Buzz - Scaling a Digital B2B Business With Dancho Dimkov, I talk about a price increase. I was having a couple of beers with my cousin, and I was sharing something that was stuck in my head. We had a client that suggested this: if he brings in potential clients for us, and if we close them, he wants a reward. And I agreed. I…
 
In episode #18 of Sweet Buzz - Scaling a Digital B2B Business With Dancho Dimkov, I talk about finding the courage to make tough decisions and take risks. Before starting BizzBee Solutions, my wife and I were digital nomads. But, we got sick of it. If we wanted to start a business, and even if we wanted to start a family - we needed to make some bo…
 
Maintaining therapeutic integrity through cryopreservation and super cold supply chains have challenged, and continue to vex, biologics producers. On this episode of the Business of Biotech, Celyad Oncology Head of Cell Therapy Manufacturing Thomas Lequertier shares best practices for the cryopreservation of cell therapies while minimizing cell deg…
 
In episode #17 of Sweet Buzz - Scaling a Digital B2B Business With Dancho Dimkov, I talk about time management for business owners. I'm trying to accomplish the perfect time balance. As I'm taking my usual morning walk, I'm recording this episode. BizzBee Solutions has grown to roughly 30 full-time employees. But, somehow, I still have to wear a lo…
 
In episode #16 of Sweet Buzz - Scaling a Digital B2B Business With Dancho Dimkov, I talk about my birthday reflection. Today is a special day, 'cause today it's my birthday. 35 is just a number for me. It's more like how I actually feel. In the last 12 months, so many things have changed. We faced (and we're still facing) a global pandemic. We were…
 
In episode #15 of Sweet Buzz - Scaling a Digital B2B Business With Dancho Dimkov, I talk about finally finishing my first book. Yay! Last week I submitted and confirmed the final version of the book. It was a challenge, no doubt. It took me two years, a great amount of effort, many sleepless nights, blood and sweat. And when I thought I was done wr…
 
Revolo Biotherapeutics has entered phase 2 clinical studies of two molecules for autoimmune or allergic diseases that act to reset the immune system “upstream,” or ahead of the inflammatory cascade. On this episode of the Business of Biotech, Revolo CEO Jonathan Rigby shares the outsourced manufacturing strategy behind the endeavor, why it's so imp…
 
Loading …

Quick Reference Guide

Copyright 2021 | Sitemap | Privacy Policy | Terms of Service
Google login Twitter login Classic login